Margaret H. Baron, MD PhD, is Fishberg Professor of Medicine; Senior Associate Dean for Education and Director of the MD-PhD Program; Director, Program in Hematology and Blood Disorders (Division of Hematology and Medical Oncology); and a member of the Tisch CancerInstitute (TCI) and Black Family Stem Cell Institute (BFSCI). She is also Program Director of an NIH-funded T32 Research Training Program in Molecular and Cellular Hematology (which can support postdoc and clinical fellows). Dr. Baron is an established scientist who has over 25 years of continuous, independent NIH-sponsored research funding in hematopoiesis and a publication record spanning protein biochemistry, virology, cell biology, developmental biology, and stem cell biology. She is known for her work on the plasticity of the differentiated state, globin gene regulation, and developmental hematopoiesis.
Dr. Baron is a graduate of the Harvard-M.I.T. Program in Health Sciences and Technology (H.S.T.) and holds degrees from Harvard (A.B.), Harvard Medical School (M.D.) and M.I.T. (Ph.D.). She trained in the laboratories of David Baltimore (Ph.D. thesis) and Tom Maniatis (postdoc). Her first independent faculty position was in The Biological Laboratories at Harvard University, where she was an assistant and then associate professor before moving to a tenured position at Mount Sinai in 1997. She served for 18 months (2006-2007) as Interim Co-Director of the BFSCI.
Dr. Baron is a dedicated educator, having developed and directed courses for undergraduates, PhD and MD/PhD students at Harvard and Mount Sinai. She is co-founder and former co-Director for the Developmental and Stem Cell Biology (DSCB) Multidisciplinary Training Area (MTA) for PhD and MD/PhD students. She is a member of the Steering Committee for the Graduate School of Biomedical Sciences and served as Assistant Director of the Medical Scientists Training Program (MSTP) and as Co-Director for the former Mechanisms of Disease and Therapies Multidisciplinary Training Area (MTA).
Cancer, Cellular Differentiation, Cytokines, Developmental Biology, Embryology, Endothelial Cells, Gene Regulation, Genetics, Growth Factors and Receptors, Hematopoiesis, Imaging, Knockout Mice, Microarray, Migration, Molecular Biology, Morphogenesis, Nucleus, Organogenesis, Protein Complexes, Regeneration, Signal Transduction, Stem Cells, Transcription Factors, Transcriptional Activation and Repression, Transgenic Mice, Transplantation, Vascular Development
Cancer Biology [CAB], Developmental and Stem Cell Biology [DSCB]
AB Summa cum laude, Harvard University
PhD, Massachusetts Institute of Technology
MD, Harvard Medical School (Harvard-M.I.T. Program in Health Sciences and Technology)
Residency, Internal Medicine, Massachusetts General Hospital
Postdoc, Harvard University
Executive Leadership in Academic Medicine (ELAM) program
Association of American Physicians (AAP)
Research Recognition Award
American Cancer Society
Irene and Dr. Arthur M. Fishberg Professor of Medicine
Mount Sinai School of Medicine
American Society for Clinical Investigation (ASCI)
Basil O'Connor Scholar Award
March of Dimes
Lucille P. Markey Charitable Trust Scholar Award
Our lab is interested in molecular mechanisms of hematopoietic stem and progenitor cell fate specification and differentiation using mouse and human primary cell and ES cell models and animals. We have a longstanding interest in developmental hematopoiesis in mammals. One focus of the lab is to study signaling pathways in embryonic hematopoiesis and erythropoiesis (red blood cells) in the mouse. A second focus is on definitive (adult type) hematopoietic and erythroid progenitor development (mouse fetal liver or bone marrow, human progenitors from peripheral blood or bone marrow). We are developing a high throughput screen for regulators of erythroid progenitors as well as later stages of maturation, including enucleation, and are targeting specific ligand-activated transcription factor pathways for detailed analysis. Experimental approaches include classical cell and molecular biology techniques, small interfering RNA viral technologies, RNA profiling and RNAseq, computational analyses, chromatin immunoprecipitation (ChIP), and genetic manipulation of mice. This work has the potential to reveal new approaches for regulating erythropoiesis and to suggest options for the development of novel therapies to improve the body’s ability to rapidly replenish its red blood cells. They may also lead to the discovery of new targets in progenitors that could be exploited to develop methods for more efficient production ex vivo of red blood cells for transfusion.
Pulina MV, Sahr KE, Nowotschin S, Baron MH, Hadjantonakis AK. A conditional mutant allele for analysis of Mixl1 function in the mouse. Genesis (New York, N.Y. : 2000) 2014 May; 52(5).
Zhang H, Nieves JL, Fraser ST, Isern J, Douvaras P, Papatsenko D, D'Souza S, Lemischka IR, Dyer MA, Baron MH. Expression of Podocalyxin separates the hematopoietic and vascular potentials of mouse ES cell-derived mesoderm. Stem Cells 2013; DOI: 10.1002/stem.1536(Epub ahead of print).
Vacaru A, Isern J, Fraser ST, Baron MH. Analysis of primitive erythroid cell proliferation and enucleation using a cyan fluorescent reporter in transgenic mice. Genesis 2013 Aug.; 51(11): 751-762.
Baron MH, Vacaru A, Nieves JL. Erythroid Development in the Mammalian Embryo. Blood Cells, Molecules and Diseases 2013; 51(4).
Baron MH. Early Embryonic Erythropoiesis … Not so Primitive After All. Stem Cells 2013; 31(5): 849-856.
Artus J, Douvaras P, Piliszek A, Isern J, Baron MH, Hadjantonakis AK. BMP4 signaling directs primitive endoderm-derived XEN cells to an extraembryonic visceral endoderm identity. Developmental biology 2012 Jan; 361(2).
Baron MH, Isern J, Fraser ST. The embryonic origins of erythropoiesis in mammals. Blood 2012 Feb; 119: 4828-4837.
Isern J, He Z, Fraser ST, Nowotschin S, Ferrer-Vacquer A, Moore R, Hadjantonakis A, Schulz V, Tuck D, Gallagher PG, Baron MH. Single Lineage Transcriptome Analysis Reveals Key Regulatory Pathways in Primitive Erythroid Progenitors in the Mouse Embryo. Blood 2011; 117: 4924-4934.
Isern J, Fraser ST, He Z, Zhang H, Baron MH. Dose-dependent regulation of primitive erythroid maturation and identity by the transcription factor Eklf. Blood 2010; 116: 3972-3980.
Zhang H, Fraser ST, Papazoglu C, Hoatlin ME, Baron MH. The Mouse Mesendoderm Gene Goosecoid is a Transcriptional Target of the Mixl1 Homeodomain Protein in Differentiating Embryonic Stem Cells. Stem Cells 2009; 27: 2884-2895.
Isern J, Fraser ST, He Z, Baron MH. The fetal liver is a niche for maturation of primitive erythroid cells. Proc Natl Acad Sci USA 2008; 105: 6662-6667.
Durand C, Robin C, Bollerot K, Baron MH, Ottersbach K, Dzierzak E. Embryonic stromal clones reveal developmental regulators of definitive hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 20838-20843.
Fraser ST, Isern J, Baron MH. Maturation and enucleation of primitive erythroblasts is accompanied by changes in cell surface antigen expression patterns during mouse embryogenesis. Blood 2007; 109: 343-352.
Haremaki T, Fraser ST, Kuo YM, Baron MH, Weinstein DC. Vertebrate Ctr1 coordinates morphogenesis and progenitor cell fate and regulates embryonic stem cell differentiation.. Proc. Natl. Acad. Sci. U.S.A 2007; 104: 12029-12034.
Willey S, Ayuso-Sacido A, Zhang H, Fraser ST, Adlam MA, Sahr K, Kyba M, Daley GQ, Keller G, Baron MH. Acceleration of Mesoderm Development and Expansion of Hematopoietic Progenitors in Differentiating ES Cells by the Mouse Mix-Like Homeodomain Transcription Factor. Blood 2006; 107: 3122-3130.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Baron during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.